zinc gluconate
Phase 3Small molecule
Johnson & Johnsonzinc gluconate is one of 4 small molecule programs targeting Noise-Induced Hearing Loss. It is currently in Phase 3.
3
Indications
10
Total Trials
3
Active Trials
3
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
2 competitors in Olfactory Dysfunction
#DrugCompanyPhaseTrials
1Medrol
PfizerPhase 2
zinc gluconate
Johnson & JohnsonPhase 3
Budesonide Nasal Spray Therapy
SSecond Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Noise-Induced Hearing Loss1 trial
Improvement of Tinnitus After Oral Zinc on Patients With Noise-induced Hearing Loss
Completed·—·N/A·NCT02951715·20 enrolled
Hyperbilirubinemia1 trial
Efficacy of Zinc in Reducing Hyperbilirubinemia Among High Risk Neonates - A Double Blind Randomized Trial
Completed·—·Phase 1/2·NCT00692224·294 enrolled
5 more indications
Olfactory Dysfunction1 trial
Low Birth Weight1 trial
Carcinoma, Non-Small-Cell Lung1 trial
Prediabetic State1 trial
Unspecified1 trial
The Individual Therapy for Patients With Wilson's Disease
Unknown status·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 1·NCT03957720·400 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for zinc gluconate. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company